Skip to main
ANIK

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics is a leading company in the early intervention orthopedics space with a diverse product portfolio and strong partnerships. The company's recent financial results beat expectations, with revenue coming in higher than anticipated and a significant increase in share repurchases. The upcoming transition in leadership to current CFO and COO, Stephen Griffin, is expected to bring continued operational improvements and a positive impact on investor confidence. Analysts also point to the potential success of the final PMA module for Hyalofast, a product for cartilage repair that recently filed its final FDA submission. With a strong balance sheet and expected revenue growth in the commercial channel, Anika is well-positioned for long-term success and we maintain an OUTPERFORM rating with a price target of $17.

Bears say

Anika Therapeutics is facing potential delays in the FDA approval process for their product Cingal, which could hinder revenue growth for the next few years. Additionally, the company's focus on internal investment and share repurchases may limit their ability to make necessary investments for future growth. Finally, their current valuation is modest and does not account for potential risks in the approval process, making their risk/reward profile unappealing.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.